Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study
Authors:
- Takanori NumataTNTakanori Numata
- Jun ArayaJAJun Araya
- Hanae MiyagawaHMHanae Miyagawa
- Keitaro OkudaKOKeitaro Okuda
- Yu FujitaYu Fujita
- Hirofumi UtsumiHUHirofumi Utsumi
- Daisuke TakekoshiDTDaisuke Takekoshi
- Mitsuo HashimotoMHMitsuo Hashimoto
- Shunsuke MinagawaSMShunsuke Minagawa
- Takeo IshikawaTITakeo Ishikawa
- Hiromichi HaraHHHiromichi Hara
- Kazuyoshi KuwanoKKKazuyoshi Kuwano
Open Access
- 1 June 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 14, 609-618
Abstract
Background: In Japan, biologic therapy was initiated for patients with severe asthma in 2009. In recent years, four biologics with different mechanisms of action have become available in the clinical setting. However, the efficacy of switching between biologics remains uncertain. Methods: To elucidate the efficacy of switching between biologics, 97 patients were enrolled who had received any biologic therapy for severe asthma at Jikei University Hospital, Tokyo, Japan, from July 2009 to December 2020. We retrospectively examined the patient characteristics, biomarkers, pulmonary function test results, selected biologics, and efficacy. Results: Thirty-one males and 66 females received any biologics. The mean age was 53.3 years at the initiation of biologic therapy. Initially, 33, 41, 15 and eight patients received omalizumab, mepolizumab, benralizumab, and dupilumab, respectively. Among three representative indicators for biologics administration, the peripheral blood eosinophil count, serum IgE levels and fractional exhaled nitric oxide, 64% of the patients had two indicators, and 28% had three indicators. Thirty-four patients (35%) switched from the initial biologic to another, and the reasons for switching included persistent asthmatic symptoms (n=22), schedule of hospital visits (n=5), and other reasons. Thus, the treatment was effective in 11 patients after switching. In addition, two patients received combination therapy with different biologics. Eighteen patients (19%) interrupted treatment for various reasons. Regardless of whether the biologic was the initial therapy, the overall efficacy of the four biologics was 60% based on the global evaluation of treatment effectiveness. Conclusion: Switching between biologics can be a promising option for severe asthma patients in whom treatment with an initial biologic is ineffective.Keywords
This publication has 39 references indexed in Scilit:
- The prevalence of severe refractory asthmaJournal of Allergy and Clinical Immunology, 2015
- The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancyJournal of Allergy and Clinical Immunology, 2015
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Exploring the Effects of Omalizumab in Allergic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Time Trend in the Prevalence of Adult Asthma in Japan: Findings from Population-Based Surveys in Fujieda City in 1985,1999, and 2006Allergology International, 2011
- The minimally important difference of the Asthma Control TestJournal of Allergy and Clinical Immunology, 2009
- ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005American Journal of Respiratory and Critical Care Medicine, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004